Novo Nordisk Shares Find Support in Wegovy Pill Data

Novo Nordisk's oral Wegovy shows greater weight loss & better tolerability vs. Eli Lilly's Foundayo in new data, aiding its fight for market share amid stock pressure.

In the highly competitive weight-loss drug sector, Novo Nordisk has released timely clinical data that bolsters the profile of its oral Wegovy treatment. This development comes just one day after U.S. regulators approved a rival pill from Eli Lilly, providing the Danish pharmaceutical giant with fresh arguments to defend its market position amid significant stock price pressure.

Clinical Edge in Efficacy and Tolerability

According to findings from the ORION study, the oral formulation of Wegovy demonstrates measurable advantages. In a simulated comparison, Novo Nordisk's 25-milligram dose achieved 3.2 percentage points greater weight reduction than the highest dose of Eli Lilly's newly approved competitor, Foundayo.

Beyond pure efficacy, the data highlights a substantial difference in patient tolerability. The study indicates that the likelihood of discontinuing treatment due to gastrointestinal issues was approximately 14 times higher with Eli Lilly's pill than with oral Wegovy. This clinical profile strongly influences patient preference: a related survey revealed that 84% of respondents favored the Wegovy pill, primarily citing its superior balance of effectiveness and side effects.

A Brief Respite for the Stock

The news prompted a modest recovery in Novo Nordisk's share price at the end of the week, with the stock advancing about 1.3% to just under $37. However, this slight uptick does little to alter the broader, challenging trend. Year-to-date, the company's shares have lost roughly 43% of their value. This substantial decline is largely driven by the looming threat of generic competitors in international markets and government-mandated price reductions, which are constraining the firm's growth.

Company leadership continues to anticipate a sales decline of between 5% and 13% for the current fiscal year 2026. In response, Novo Nordisk is focusing on new combination therapies and, critically, expanding its oral medication segment to steer a turnaround.

The Evolving Oral Treatment Landscape

While Eli Lilly plans to begin shipments of Foundayo on April 6, the Wegovy pill has been commercially available since January. Market researchers from William Blair and BMO Capital Markets project that injectable treatments, due to their higher efficacy, will continue to dominate the U.S. market, capturing around 80% of the long-term share. Nevertheless, the latest clinical results provide Novo Nordisk with a solid foundation to aggressively compete for the remaining 20% oral segment against its new rival.